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Abstract: Ligand-based NMR techniques to study protein–
ligand interactions are potent tools in drug design. Satura-
tion transfer difference (STD) NMR spectroscopy stands out
as one of the most versatile techniques, allowing screening
of fragments libraries and providing structural information
on binding modes. Recently, it has been shown that a multi-
frequency STD NMR approach, differential epitope mapping
(DEEP)-STD NMR, can provide additional information on the
orientation of small ligands within the binding pocket. Here,
the approach is extended to a so-called DEEP-STD NMR fin-
gerprinting technique to explore the binding subsites of
cholera toxin subunit B (CTB). To that aim, the synthesis of a
set of new ligands is presented, which have been subject to
a thorough study of their interactions with CTB by weak af-
finity chromatography (WAC) and NMR spectroscopy. Re-
markably, the combination of DEEP-STD NMR fingerprinting
and Hamiltonian replica exchange molecular dynamics has
proved to be an excellent approach to explore the geome-
try, flexibility, and ligand occupancy of multi-subsite binding
pockets. In the particular case of CTB, it allowed the exis-
tence of a hitherto unknown binding subsite adjacent to the
GM1 binding pocket to be revealed, paving the way to the
design of novel leads for inhibition of this relevant toxin.
Introduction
In the context of drug discovery, fragment-based drug discov-
ery (FBDD) has gained momentum over the last decade as a
method for lead generation.[1] The technique relies on screen-
ing small compounds against a pharmacologically relevant
target to find fragments with low affinity towards some of the
adjacent binding subsites of which the target’s binding pocket
can be formally thought as composed of. The binding frag-
ments are then combined together to obtain potent leads. In
the FBDD approach, detailed information on the target struc-
tural features is in fact necessary.[2]
On these premises, it is not surprising that NMR spectrosco-
py is one of the elected methods to rationally design novel
drugs by using FBDD, particularly for low affinity binders,
which tend to generate protein–ligand complexes that are dif-
ficult to crystallize. Back in 1997, the first NMR methodology
for efficient ligand screening and lead design was proposed:
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“SAR by NMR” (structure–activity relationship by NMR).[3] In
SAR by NMR, isotopically labeled proteins are studied with
each fragment of a particular library, and chemical shift pertur-
bations allow, upon protein assignment, identification of differ-
ent subsite binders. Analysis of further NOESY experiments
gives rational directions to connect fragments, to obtain very
high affinity leads.[3] A complementary approach, based on ob-
servation of NMR signals of the binder, is the use of ligand-
based NMR techniques.[4] Within this approach, one decade
later, Pellecchia and co-workers proposed a method based on
transfer-NOESY experiments : “SAR by Inter-Ligand NOE” (ILOE).
Without the need of labeling and spectroscopic assignment of
the targets, it is possible to study a small pool of fragments,
accommodated in different adjacent binding subsites within a
binding pocket, and provide points of contact between them
to obtain inhibitors of nanomolar potency.[5]
Among ligand-based NMR approaches, Saturation Transfer
Difference NMR (STD NMR)[6] spectroscopy has proved itself to
be an efficient and reliable tool in FBDD, allowing us to dis-
criminate between specific and unspecific binders, even when
they are analyzed as a pool.[7] We have recently proposed an
expansion of the methodology termed Differential Epitope
Mapping STD NMR (DEEP-STD NMR) based on the new con-
cept of multi-frequency STD NMR experiments.[8] In DEEP-STD
NMR spectroscopy, two binding epitope mappings are deter-
mined, following the use of two different frequencies for pro-
tein saturation, in contrast to a single one as in standard STD
NMR. By changing the on-resonance frequency, different types
of side chains in the binding pocket will reach slightly different
levels of saturation and those differences can be picked up by
building a differential epitope mapping, where the differences
between the two mappings are revealed. Those differences in-
dicate proximity to the type of protein side chain directly irra-
diated in each experiment, providing information on the type
of amino acid side chain surrounding a proton of the ligand,
as well as hinting about the orientation of the ligand relative
to the side chains lining the binding pocket. This way, further
to identifying selective binders, the technique allows us to de-
termine the orientation of the fragments in the binding sub-
sites. This is extremely valuable information when it comes to
drug design, and previous results from our laboratory have
shown DEEP-STD NMR to be a very informative tool in the dis-
covery of WWP2 ubiquitin ligase inhibitors.[9]
Here, we have applied DEEP-STD NMR spectroscopy, com-
bined with advanced molecular dynamics simulations to ex-
plore the plasticity and dynamics of the multi-subsite binding
pocket of cholera toxin B (CTB). The interaction between CTB
and its natural substrate, the glycolipid ganglioside GM1, is
one of the strongest and best studied protein–carbohydrate
interactions known, and is biologically highly relevant, as it
mediates the onset of the cholera infection.[10] Currently, still,
cholera treatment mainly resorts to antibiotics, but the appear-
ance of antibiotic resistant V. cholera strains[11] have triggered
the development of alternative cures for this endemic dis-
ease.[12] Large efforts have been reported towards the design
of inhibitors of the GM1/CTB interaction. Structural and ther-
modynamic studies on this complex showed that high specific-
ity is given by the presence of two adjacent binding subsites,
accommodating the two “arms” of the GM1 ligand, that is, the
galactose and sialic acid non-reducing ends.[13, 14, 15] Grounded
in this knowledge, many carbohydrate-based scaffolds have
been designed that aim to target both binding subsites.[16–20]
Despite these glycomimetics showing very good affinity
levels, the challenge has remained to overcome the problem
of hydrolyzability. In our labs, we have reported that CTB li-
gands based on thio-galactosides bearing a polyhydroxyalkyl-
furoate moiety (PHF), showed promise as non-hydrolyzable in-
hibitors.[21] The PHF moiety was demonstrated to contribute ef-
fectively to the affinity for CTB, and STD NMR studies on three
representatives of this family of CTB ligands (Figure 1, com-
pounds 1–3) supported a bidentate binding mode, so that
both the galactose ring and the PHF moiety are the main con-
tacts with the protein in the bound state of ligand 3.
In this work, we present the synthesis of a new set of CTB li-
gands to explore the GM1 binding pocket of CTB and propose
the DEEP-STD NMR fingerprinting protocol, to gain orientation-
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Figure 1. Structure of ligands 1, 2, and 3[21] and the novel set of thio-galacto-
side CTB ligands 4–9 described in this work.
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al information on the ligands in the subsites by comparison to
DEEP-STD NMR data of a binder with a known 3D structure of
its complex to CTB. The combination of STD NMR competition
experiments,[22] ILOEs,[23] docking,[24–26] advanced molecular dy-
namics,[27] and STD NMR intensity prediction from 3D molecu-
lar models of the complexes using CORCEMA-ST,[28] has allowed
us to answer the question of how large and flexible ligands
like 3 can be accommodated in the GM1 binding pocket of
CTB, demonstrating the existence of a hitherto unknown bind-
ing subsite adjacent to the GM1 binding pocket, paving the
way to the design of novel non-carbohydrate leads for CTB in-
hibition.
Results and Discussion
A novel set of promising small-molecule CTB inhibitors are de-
veloped to explore the binding subsites of the GM1 binding
pocket of CTB by DEEP-STD NMR fingerprinting. The STD NMR
results previously obtained for CTB ligand 3[21] indicated that
both (galactose and benzyl) ends of the binder established the
closest contacts with CTB in the bound state, whereas the pol-
yhydroxyalkyl spacer made less contact with the protein. As no
3D structure of the 3/CTB complex is available, this result
could be interpreted as a simultaneous binding of both ends
to the galactose and sialic acid subsites within the GM1 bind-
ing pocket of CTB (bidentate bound mode). Based on these re-
sults, we first wanted to experimentally probe the role in CTB
binding of the polyhydroxyalkyl spacer linking both ends in 3,
to inform the size optimization of novel CTB ligands. To that
aim, we designed a novel set of shorter thio-galactoside li-
gands (compounds 4–9, Figure 1) lacking the triazole-polyhy-
droxyalkyl linker present in 2 and 3 and that instead have the
thio-galactose residue directly connected to the benzyl furoate
moiety. The variability across the compound set is given by the
anomeric configuration (a or b) and the oxidation state of the
glycosidic sulfur (present as a thioether, sulfone, or sulfoxide
functional group), for a total of six new compounds (Figure 1).
The synthesis of a-galactosides 5, 7, and 9 (Scheme 1) start-
ed from peracetylated thioglycosides 13.[29] Selective S-deace-
tylation followed by reaction with chloro derivative 11 b afford-
ed a-thioglycoside 15 in 48 % yield. Compound 11 b was pre-
pared from polyhydroxyalkylfuroate 10,[21] after oxidation with
NaIO4 followed by reduction with NaBH4 and chlorination. Sub-
sequent nucleophilic displacement with KSAc and deacetyla-
tion afforded thiol 12 b in good overall yield, which after reac-
tion with penta-O-acetyl-a-d-galactopyranosyl bromide 14 ex-
clusively gave b-thioglycoside 16. Oxidation of 15 and 16 with
MCPBA (meta-chloroperoxybenzoic acid) under different reac-
tion conditions afforded sulfone derivatives 17 and 18 and
sulfoxides 19 and 20. Final deacetylation of compounds 15–20
under Zempl8n conditions gave compounds 4–9 in 65–99 %
yield.
The interactions of 4–9 with CTB were first studied by weak
affinity chromatography (WAC),[30] and the KD values are shown
in Table 1. The new ligands showed KD values ranging from
0.35 mm to 0.48 mm, coming across as very promising CTB
binders compared with 1–3, for which the KD values were in
the low mm range.[21]
STD NMR experiments were carried out to confirm the bind-
ing to CTB for all the members of the set 4–9, and to get struc-
tural information on their binding modes.
Table 1. KD values for the binding of ligands 4–9 to CTB, as determined
by WAC.
Compound Glycosidic bond X, X1 KD [mm]
4 b none, none 0.35
5 a none, none 0.26
6 b O, O 0.34
7 a O, O 0.34
8 b O, none 0.45
9 a O, none 0.48
Scheme 1. Reagents and conditions: a) 1) NaIO4, H2O/MeOH, 0 8C!RT;
2) NaBH4, MeOH, RT; b) NCS, Me2S, CH2Cl2, @20!0 8C; c) KSAc, DMF, 50 8C;
d) NaOMe, MeOH, 0 8C; e) EtNH2, DMF, RT; f) aq. Na2CO3, EtOAc, TBAHS, RT;
g) MCPBA, CH2Cl2, RT; h) MCPBA, CH2Cl2, @78!@30 8C.
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The determined binding group epitope mappings of their
interactions with CTB showed a significant degree of variability
among the six ligands (Figure 2), even at the common galac-
tose ring. This was surprising, as the GM1 binding pocket of
CTB provides a specific galactose subsite, which called for fur-
ther investigation. To that aim, we resorted to our recently de-
veloped DEEP-STD NMR method[8] to elucidate the ligand ori-
entation in the bound state.
“DEEP-STD NMR fingerprinting” characterizes the bound
orientations of 4–7 in the GM1 binding pocket of CTB
DEEP-STD NMR spectroscopy is a novel tool for revealing the
bioactive orientation of ligands in a protein binding pocket, if
the 3D geometry of the binding pocket is known.[8] The availa-
bility of a crystal structure of the complex of CTB with a small
galactoside derivative, 3-nitrophenyl-a-d-galactopyranoside,
3NPG (PDB ID: 1EEI),[31] encouraged us to propose a novel
method that we call “DEEP-STD NMR fingerprinting”. First, the
DEEP-STD NMR pattern of 3NPG in complex with CTB is deter-
mined, providing DEEP-STD factors, DSTD, which can be direct-
ly correlated with the orientation of 3NPG in the crystal struc-
ture (i.e. , which ligand protons are close to a given type of
amino acid side chain[8]). Then, the patterns of DEEP-STD fac-
tors of the “unknown” ligands (4–9) are determined and com-
pared with that of 3NPG. This approach, first, allows us to con-
firm the binding of unknown ligands to a known binding
pocket and, second, it sheds light on their relative orientation,
in comparison to the orientation of known ligands.
We carried out the DEEP-STD NMR fingerprinting of the GM1
binding pocket of CTB with 3NPG[8] and ligands 4–7 (ligands 8
and 9 were excluded owing to degradation over the time of
the experiments). We irradiated the different samples contain-
ing the CTB/ligand complexes at 0.60 ppm and 2.25 ppm (on-
resonance frequencies), as already reported for the 3NPG/CTB
complex.[8] At 2.25 ppm, the glutamate and glutamine side
chains in the galactose subsite are directly irradiated, and at
0.60 ppm the irradiation is on the aliphatic side chains.
The determined DSTD (2.25 ppm/0.60 ppm) for each com-
plex are shown in Figure 3 (see also the Supporting Informa-
tion, Figure S2). The overall positive DSTD values at the galac-
tose protons for all the ligands 4–7 (Figure 3 a) indicate that
the thio-galactose ring is allocated in the galactose binding
subsite of the GM1 pocket, by comparison with the positive
DSTDs observed for the 3NPG/CTB complex (Figure 3 b). Still,
differences in DSTDs were noticeable for some galactose pro-
tons of 4–7, suggesting some reorientation of the galactose
moiety in the galactose subsite, which results from the chemi-
cal differences at the benzyl furoate side of the molecules, in
good agreement with the experimental binding epitope data
(Figure 2).
Molecular docking: ligands 4–7 bind CTB by occupying the
GM1 galactose and sialic acid subsites
We performed rigid molecular docking simulations of li-
gands 4–7 by using the crystal structure of CTB in the GM1/
CTB complex (PDB ID: 3CHB).[32] For each ligand, the lowest
energy solutions converged to a binding mode in which the
thio-galactose moiety sits in the galactose binding subsite and
the furoate-benzyl tail lies in the sialic acid binding subsite
within the GM1 binding pocket of CTB (Figure 4).
Remarkably, the galactose ring of the four ligands showed
different orientations within the subsite, in good agreement
Figure 2. STD NMR binding epitope mapping of ligands 4–9, based on the
normalized STD values from the initial slope of each proton, relative to the
most intense one (for which 100 % is arbitrarily assigned). Legend indicates
weak (blue), medium (yellow), and strong (red) intensities (closer contacts
with CTB). Proton assignment of the ligands, raw build-up curves data, and
normalized STD values are reported in the Supporting Information.
Figure 3. Differential epitope mapping DSTD (2.25 ppm/0.60 ppm) of a) li-
gands 4–7 and b) 3NPG in complex with CTB (reference sample), obtained at
2 s saturation time. For each ligand, the three largest positive DSTD values
are shown as orange bars. c) Crystal structure of the complex 3NPG/CTB
(PDB ID: 1EEI).[31] Protein protons directly irradiated at 2.25 ppm are high-
lighted with an orange surface.
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with the experimental NMR observations (Figures 2 and 3). On
the contrary, the benzyl groups of all the four ligands con-
verged into a single orientation in the adjacent sialic acid sub-
site (blue surface in Figure 4 a), where a stabilizing p-stacking
with Tyr12 can take place (Figure 4 c).
These results agree with previous studies showing that CTB
ligands with aromatic rings can efficiently p-stack with Tyr12 in
the sialic acid binding subsite.[31, 33] On the other hand, li-
gands 4–7 fine-tune the orientation of their thio-galactose
moieties within the binding subsite by favorable contacts with
the amide group of Asn14 and/or the NH group of the side
chain of Trp88 present at the protein surface (Figure 4 b). The
impact on galactose orientation is substantial for the sulfone
epimers, which can form hydrogen-bonds with Asn14 and
Trp88 through their two oxygens (Figure 4 b), disrupting the
hydrogen-bond network of the galactose ring in the natural
ligand GM1 and altering its orientation.
Globally, the 3D molecular models of the complexes of CTB
with ligands 4–7, in agreement with the DEEP-STD NMR finger-
printing approach, demonstrate that small galactoside-based li-
gands armed with a benzyl furoate tail bind the GM1 pocket in
CTB in a bidentate mode, simultaneously occupying the galac-
tose and sialic acid subsites. Decorations at the glycosidic link-
age have a sensitive impact on the binding mode of the galac-
tose ring. This is relevant for the design of CTB inhibitors
based on mimicking the GM1 galactose, as the sulfone affects
the mimicry of the galactose orientation in the GM1 natural
ligand.
How do larger ligands 2 and 3 occupy the GM1 binding
pocket? STD NMR competition experiments suggest the pres-
ence of an unknown subsite. In the complexes of CTB with li-
gands 4–7, the whole GM1 binding pocket is very efficiently
occupied (Figure 4) with all parts of the relatively small ligand
being intimately recognized by the protein (Figures 2 and 4).
This result prompted the question of how a larger ligand, like
3, is able to be accommodated in the pocket. Binding group
epitope mappings of ligands 2 and 3 for their interactions
with CTB have already been reported,[21] supporting a biden-
tate mode of binding and showing that the spacer linking
both ligand ends also establishes contacts with the protein
(Supporting Information, Figure S1).[21] Interestingly, ligand 2
and the PHF tail of ligand 3 showed similar binding epitope
mappings, strongly suggesting that both bind into the same
CTB subsite (Supporting Information, Figure S1).
Owing to the non-carbohydrate nature of the PHF end pres-
ent in ligands 2 and 3, and their larger size, in comparison to li-
gands 4–7, the question arises as to whether these ligands
might be interacting in a binding site other than the sialic acid
subsite of the GM1 pocket. Here, we tested this hypothesis
and aimed to provide 3D models of the complexes of 2 and 3
with CTB, validated by NMR spectroscopy.
We started by exploring the occupancy of the two (galac-
tose/sialic acid) binding subsites of CTB by STD NMR competi-
tion experiments. To that aim, we selected STD-active probe li-
gands known to occupy either subsite in the GM1 binding
pocket of CTB (we call them subsite “reporters”) and probed
whether any of the ligands 2 or 3 were able to displace any of
the reporters in competition experiments. 3NPG was used as
the galactose subsite reporter and 3’-sialyllactose (3’SL), the
Neu5Ac-containing branch of GM1, as the reporter for the
sialic acid subsite (Figure 5).
First (Table 2, experiment a), STD NMR signals of a sample
containing ligand 3 and CTB were observed and its competi-
tion with the galactose subsite reporter 3NPG was monitored.
In this experiment, 3NPG displaced ligand 3 when added to
the solution in an equimolar amount (Supporting Information,
Figure S3 a). Upon addition of 3NPG, the STD signals of
ligand 3 were halved, in agreement with their similar KD (3NPG
1.10 mm vs. ligand 3 1.05 mm),[21] confirming that the thio-gal-
actose moiety of ligand 3 binds to the galactose subsite within
the GM1 binding pocket.
Figure 4. a) Lowest-energy docking solutions for ligand 4 (gray), ligand 6
(pink), ligand 5 (green), and ligand 7 (violet) in complex with CTB. The resi-
dues lining the galactose and sialic acid binding subsites are highlighted
with orange and blue surfaces, respectively. b) On a semi-transparent sur-
face, the sulfone oxygen atoms of 6 and 7 are shown pointing towards
Asn14 and Trp88 (in turquoise sticks), and the methyl group on the furoate
pointing parallel to His13 (red sticks), rather than towards Gln61 (turquoise
sticks). c) Zoom on the phenyl moieties of ligands 4–7, showing the interac-
tion with Tyr12 (turquoise sticks).
Figure 5. Chemical formulae for 3-nitrophenyl a-d-galactopyranoside (3NPG;
reporter for the Gal subsite) and 3’-sialyllactose (3’SL; reporter Neu5Ac sub-
site).
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After that, we probed the competition between ligands 2
and 3, so ligand 2 was added at an equimolar amount to a
sample of ligand 3 in complex with CTB (Table 2, experiment
b). In this case, the STD signals of ligand 3 dropped upon addi-
tion of ligand 2 (Supporting Information, Figure S3 b), which
has a KD = 1.35 mm,
[21] proving that both ligands 3 and 2
occupy a common subsite, most likely through their common
PHF tail.
Then, ligand 2 was tested in competition with 3NPG
(Table 2, experiment c). No competition was observed in this
case, showing that the binding of ligand 2 to CTB does not in-
volve the galactose subsite (Supporting Information, Fig-
ure S3 c).
Finally, to investigate if the PHF tail binds to CTB in the sialic
acid subsite, the competition experiment between 3’SL and
ligand 2 was carried out (Table 2, experiment d). Binding of
3’SL was detected (Supporting Information, Figure S5), but the
STD signals of 3’SL were not affected by the addition of
ligand 2 (Supporting Information, Figure S3 d). As a control,
adding 3’SL to a sample containing CTB and ligand 2, did not
affect the signals of 2 either (Supporting Information, Fig-
ure S3 e), confirming that binding of ligands 3 and 2 does not
involve the sialic acid subsite. Globally, the STD NMR competi-
tion experiments strongly support the existence of an un-
known subsite on CTB, which is able to accommodate the PHF
tails in ligands 2 and 3.
ILOE experiments exploring subsites proximity in the GM1
binding pocket of CTB
The scenario depicted by the STD NMR competition experi-
ments did not exclude that ligands 3 and 2 could compete for
a subsite outside the GM1 binding pocket. On the other hand,
as previously observed (experiment c, Table 2), 3NPG and
ligand 2 can bind simultaneously to CTB. On this basis, we de-
cided to test experimentally if they bind in proximity to each
other (adjacent binding subsites) by generating the 2/CTB/
3NPG ternary complex in solution and resorting to an ILOE (tr-
NOESY) experiment[23] (Figure 6).
In the tr-NOESY spectrum of the ternary complex, we did
observe an inter-ligand 2–3NPG cross peak between the tria-
zole proton (Htriaz) of ligand 2 (7.67 ppm) and the Hc,d protons
of 3NPG (positions meta and para to the nitro group, both at
7.27 ppm), along with the expected intra-ligand cross peaks
for both ligands. As a control, to confirm the inter-ligand
nature of that NOE, the same tr-NOESY experiment was per-
formed on the binary 3NPG/CTB and ligand 2/CTB complexes
as well as on CTB alone (see the Supporting Information, Figur-
es S5 and S6 for control and full spectral width spectra of the
ternary complex). The 7.67 ppm/7.27 ppm cross peak was
absent in the three control spectra, confirming that the cross
peak is not due to any protein–ligand or protein–protein NOE,
but it genuinely reports a close contact (ILOE) between the tri-
azole moiety of ligand 2 and the nitrophenyl group of 3NPG in
the bound state.
The observation of this inter-ligand 2–3NPG NOE in the state
bound to CTB is of paramount importance in our study, as it
proves the existence of a subsite accommodating the furoate-
benzyl chain, adjacent to the galactose subsite, but different to
the sialic acid subsite. To generate 3D models of the com-
plexes with 2 and 3, we then focused our structural search on
the proximities of the GM1 binding pocket. Furthermore, the
observed ILOE gave us information on the orientation of
ligand 2 in this novel subsite, which is such that its triazole is
in proximity of the galactose subsite.
Hamiltonian replica exchange molecular dynamics (HREMD)
reveals a novel subsite in the GM1 binding pocket that accom-
modates the polyhydroxyalkylfuroate tail of 2 and 3. In con-
trast to the smaller ligands 4–7, docking calculations of ligands
2 and 3 into the GM1 binding pocket of CTB failed to generate
3D models that could agree with the experimental data (see
the Supporting Information). STD predictions from the docking
models were obtained by using CORCEMA-ST.[28] Predicted STD
intensities are compared with experimental NMR data through
Table 2. Table of results of the competition experiments (for the STD
spectra, see the Supporting Information, Figure S3).
Experiment Ligand Competitor Displacement
a) 3 3NPG P
b) 3 2 P
c) 2 3NPG O
d) 3’SL 2 O
Figure 6. Top) Expansion of the superposition of tr-NOESY experiments of
the 2/3NPG/CTB ternary complex (in black) and of the 3NPG/CTB control
complex (in red). Diagonal and cross peaks are assigned and the ILOE peak
correlating Hc,d of 3NPG and Htriaz of ligand 2 are highlighted in blue. Bot-
tom) Magnification of the ILOE cross peak. Signals belonging to ligand 2 and
3NPG are marked with a red asterisk and a black hashtag, respectively.
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the so-called NOE R-factor, with a low value indicating a good
matching. In our experience, values ,0.3 report good agree-
ment between the 3D model and the experimental data. The
PHF tail of 3 was predicted to occupy the sialic acid subsite, in
disagreement with STD NMR competition experiments and
binding epitopes, as quantitated by the high NOE R-factor
(Supporting Information, Figure S11). Similarly, docking solu-
tions for ligand 2 also showed high NOE R-factors (Supporting
Information, Figure S12).
Taking into account the ILOE results, we then decided to in-
vestigate the dynamics of the GM1 binding pocket in CTB to
probe the flexibility of side chains in the vicinity of the galac-
tose and sialic acid subsites. To that aim, a 100 ns molecular
dynamics (MD) simulation of free CTB was performed. To en-
hance sampling of the free state, an HREMD-based method
was chosen in which the non-bonding interaction between the
solvent and hydrophobic regions of the protein were modified
in each replica, which has previously been shown to be effec-
tive in identifying druggable transient binding sites.[27]
Analysis of the trajectory over all five subunits of the CTB
pentamer revealed the existence of a transient subsite close to
the galactose and sialic acid subsites (Figure 7 and Supporting
Information, Figure S13). Although this subsite is closed in the
crystal structure, opening is facilitated by rotation of the Ile59
and Lys138 side chains (Figure 7). As no main chain rearrange-
ment is observed, the energy barrier between the ‘closed’ and
‘open’ conformations is expected to be minimal such that
both states are readily sampled in the unbound protein.
Furthermore, repeating the simulation with CTB bound to
GM1 revealed that opening of this cryptic subsite still takes
place in the presence of the native ligand (Supporting Informa-
tion, Figures S14 and S15). This shows that this subsite is ac-
cessible even when the galactose and sialic acid subsites are
engaged in binding, opening the door to further CTB inhibitor
design that could exploit all three subsites.
We then carried out docking calculations of ligand 3 to this
‘open’ conformation. The best docking solutions showed
indeed that the PHF moiety occupies the novel subsite, in ad-
dition to good convergence at the galactose end towards the
galactose subsite (Figure 8, ligand 3 in yellow). Furthermore, a
long MD simulation of this complex indicated that this confor-
mation is dynamically stable, and, most importantly, the novel
subsite is occupied for most of the simulation (Supporting In-
formation, Figures S16 and S17).
The same approach was followed for ligand 2 to generate a
3D model of ligand 2 bound in the open conformation of CTB
(Figure 8, ligand 2 in light red). Long MD simulation revealed
even greater dynamic stability than the 3/CTB complex, with
the furoate-benzyl chain exclusively occupying the novel sub-
site throughout the simulation. Without a galactose moiety to
act as an anchor, ligand 2 buries itself further into the hydro-
phobic binding subsite (Figure 8). Moreover, the basic side
chain of Lys138 is able to form several favorable hydrogen-
bonding interactions with the furoate-benzyl moiety, which are
not possible for ligand 3.
Finally, the 3D models of the complexes were validated
against the experimental NMR data by using CORCEMA-ST. In-
stead of considering a single docking solution, STD NMR inten-
sities were predicted running CORCEMA-ST on a set of 100
frames from each of the MD simulations of the complexes of li-
gands 2 and 3 with CTB, to reflect the flexibility of the systems.
The agreement with the experimental data was very good,
with NOE R-factors of 0.25 and 0.31, respectively (Supporting
Information, Figures S18 and S19). These results confirm that,
in solution, the novel binding subsite in the GM1 binding
pocket of CTB is populating the open state and can accommo-
date the PHF tail in the bound state to ligands 2 and 3.
Figure 7. Opening of a novel subsite in the GM1 binding pocket of CTB.
Top) In green, the conformations of the side chains of Ile58 and Lys34 in the
crystal structure of CTB (PDB ID:3CHB); in turquoise, overlaid, the open state
of the novel subsite from HREMD simulations. The red arrows indicate the
c1 torsional rotation from closed to open states for the two residues in-
volved (c1 values reported for both). Bottom) Surface representation of the
closed (left) and open conformations (right), corresponding to initial and
final frames of the HRMED apo CTB simulation. Galactose binding subsite in
orange; sialic acid binding subsite in blue; Ile58 and Lys34 in green and la-
beled.
Figure 8. Superposition of the representative MD frames of the most popu-
lated clusters of the complexes of CTB with ligand 3 (pale yellow) and
ligand 2 (light red) bound to CTB in the “open” conformation. The galactose
subsite is in orange and the sialic acid subsite is in blue; Lys34 and Ile58, de-
fining the novel subsite, in green.
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Conclusion
In this work, we have shown that our novel DEEP-STD NMR fin-
gerprinting approach, combined with MD simulations, is a very
powerful tool to explore the multi-subsite architecture of pro-
tein binding pockets. Here, we have applied it to an important
drug target, that is, cholera toxin subunit B (CTB), but the ap-
proach is expected to be of broad applicability in the investi-
gation of ligand binding to other multi-subsite relevant tar-
gets.
To explore the binding subsites of CTB, six novel thio-galac-
tosidic CTB inhibitors (4–9) were synthesized and studied.
These showed a much higher affinity for CTB, relative to their
precursors.[21] Structural analysis revealed that, for the six li-
gands, the aromatic moiety sits in the sialic acid binding sub-
site of GM1, p-stacking with the underlying side chain of
Tyr12. On the other hand, the decoration at the thio-glycosidic
linkage and the variability of the anomeric configuration dis-
rupt the mimicry of the galactose ring in the binding subsite
of GM1.
For the larger ligands 2 and 3,[21] a combination of STD NMR
competition and ILOE experiments, as well as docking and
Hamiltonian replica exchange molecular dynamics (HREMD) al-
lowed us to unveil the existence of a novel cryptic binding
subsite on the GM1 binding pocket of CTB. This subsite was
not present in the rigid crystal structure of CTB bound to GM1,
but molecular dynamics revealed that it can be readily formed
by rearrangements in the side chains of Ile59 and Lys138,
which are adjacent to the known galactose and sialic acid
binding subsites at the GM1 binding pocket. 3D models of the
complexes, generated by MD simulations combined with STD
NMR spectroscopy and validated by using CORCEMA-ST, dem-
onstrated that ligands 2 and 3 occupy this subsite with their
polyhydroxyalkylfuroate tails. The existence of this new non-
carbohydrate binding subsite in CTB, accessible even when the
two known subsites are occupied, paves the way for future
design of three-finger thio-galactose mimetics as potentials
CTB inhibitors.
Experimental Section
Materials
3-Nitrophenyl a-d-galactopyranoside (3NPG), cholera toxin subunit
B, deuterium oxide (99.9 % 2H), dimethyl sulfoxide-d6 ([D6]DMSO),
disodium hydrogen phosphate (Na2HPO4), potassium dihydrogen
phosphate (KH2PO4), sodium chloride (NaCl), and potassium chlo-
ride (KCl) were purchased from Sigma–Aldrich. Ligands were pre-
pared in stock solutions 3 % [D6]DMSO.
Synthesis and characterization. General
Optical rotations were measured in a Jasco P-2000 spectropolarim-
eter in a 1.0 cm or 1.0 dm tube (Na, l 598 nm). Infrared spectra
were recorded with a Jasco FTIR-410 spectrophotometer. d are
given in ppm and J in Hz. J are assigned and not repeated. All the
assignments were confirmed by 2D spectra (COSY and HSCQ). High
resolution mass spectra were recorded on a Q-Exactive spectrome-
ter. TLC was performed on silica gel 60 F254 (Merck), with detection
by UV light charring with H2SO4 or with reagent [(NH4)6MoO4,
Ce(SO4)2, H2SO4, H2O]. Silica gel 60 (Merck, 40-60 and 63-200 mm)
was used for preparative chromatography.
Synthesis of ligands 4–9
((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-thio-b-d-gal-
actopyranoside (4): To a solution of 16 (40 mg, 0.066 mmol) in an-
hydrous MeOH (2 mL), NaOMe (13 mL, 0.5 m in MeOH) was added
and the mixture stirred at 0 8C for 2 h. Then, the mixture was neu-
tralized with Amberlite IR-120H+ , filtered, and washed with MeOH.
The filtered solution was concentrated to give pure 4 (26 mg,
0.061 mmol, 92 %) as a pale-yellow oil. a½ A23D =@104.8 (c = 0.64,
MeOH); IR: = 3381 (OH), 2907, 1705 (C=O), 1072 cm@1; 1H NMR
(300 MHz, CD3OD): d= 7.43–7.31 (m, 5 H, H-Ar), 6.52 (s, 1 H, H-3’),
5.26 (s, 2 H, CH2Ph), 4.28 (d, 1 H, J1,2 = 9.6 Hz, H-1), 4.03 (d, 1 H,
2JH,H = 14.5 Hz, CH2S), 3.87 (dd, 1 H, J4,3 = 3.2, J4,5 = 0.6 Hz, H-4), 3.78
(d, 1 H, 2JH,H = 14.5 Hz, CH2S), 3.76 (dd, 1 H,
2J6a,6b = 11.5, J6a,5 = 7.1 Hz,
H-6a), 3.68 (dd, 1 H, J6b,5 = 5.1 Hz, H-6b), 3.57 (t, 1 H, J2,3 = 9.5 Hz, H-
2), 3.51–3.47 (m, 1 H, H-5), 3.41 (dd, 1 H, H-3), 2.52 ppm (s, 3 H, Me);
13C NMR (75.4 MHz, CD3OD): d= 165.2 (COOBn), 160.4, 151.4 (C-2’,
C-5’), 137.7 (Cq-Ar), 129.6, 129.2, 129.1 (C-Ar), 115.0 (C-4’), 109.3 (C-
3’), 86.1 (C-1), 80.8 (C-5), 76.3 (C-3), 71.4 (C-2), 70.5 (C-4), 67.0
(CH2Ph), 62.7 (C-6), 26.2 (CH2S), 13.9 ppm (Me); HRESIMS: m/z
found: 447.1079; calcd For C20H24O8NaS (M + Na)
+ : 447.1084.
((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-thio-a-d-
galactopyranoside (5): To a solution of 15 (47 mg, 0.079 mmol) in
anhydrous MeOH (1.5 mL), NaOMe (16 mL, 0.5 m in MeOH) was
added and the mixture stirred at 0 8C for 1.5 h. Then, the mixture
was neutralized with Amberlite IR-120H+ , filtered, and washed
with MeOH. The filtered solution was concentrated to give pure 5
(34 mg, 0.079, quantitative) as a white solid. a½ A25D = 249.8 (c = 0.68,
MeOH); IR: = 3382 (OH), 2927, 1708 (C=O), 1069 cm@1; 1H NMR
(300 MHz, CD3OD): d= 7.43–7.29 (m, 5 H, H-Ar), 6.50 (s, 1 H, H-3’),
5.35 (d, 1 H, J1,2 = 5.7 Hz, H-1), 5.25 (s, 2 H, CH2Ph), 4.16 (t, 1 H, J5,6 =
6.2 Hz, H-5), 4.09 (dd, 1 H, J2,3 = 10.0 Hz, H-2), 3.89 (d, 1 H, J4,3 =
2.4 Hz, H-4), 3.82 (d, 1 H, 2JH,H = 14.9 Hz, CH2S), 3.76–3.68 (m, 2 H, H-
6), 3.65–3.59 (m, 2 H, H-3, CH2S), 2.52 ppm (s, 3 H, Me);
13C NMR
(75.4 MHz, CD3OD): d= 165.2 (COOBn), 160.4, 151.4 (C-2’, C-5’),
137.7 (Cq-Ar), 129.6, 129.21, 129.19 (C-Ar), 115.0 (C-4’), 109.1 (C-3’),
85.8 (C-1), 73.0 (C-5), 72.3 (C-3), 70.9 (C-4), 69.5 (C-2), 67.0 (CH2Ph),
62.7 (C-6), 25.2 (CH2S), 13.8 ppm (Me); HRESIMS: m/z found:
447.1072; calcd For C20H24O8NaS (M + Na)
+ : 447.1084.
((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-sulfonyl-b-
d-galactopyranoside (6): To a solution of 18 (60 mg, 0.096 mmol)
in anhydrous MeOH (2 mL), NaOMe (20 mL, 0.5 m in MeOH) was
added and the mixture stirred at 0 8C for 1 h. Then, the mixture
was neutralized with Amberlite IR-120H+ , filtered, and washed
with MeOH. The filtered solution was concentrated and the residue
was purified by column chromatography on silica gel (CH2Cl2/
MeOH 10:1!8:1) to give 6 (33 mg, 0.072 mmol, 75 %) as a white
solid. a½ A23D =@25.0 (c = 0.84, MeOH); IR: = 3382 (OH), 2920, 1711
(C=O), 1082 cm@1; 1H NMR (300 MHz, CD3OD): d= 7.44–7.29 (m, 5 H,
H-Ar), 6.86 (s, 1 H, H-3’), 5.28 (s, 2 H, CH2Ph), 4.76 (d, 1 H,
2JH,H =
15.0 Hz, CH2S), 4.49 (d, 1 H, CH2S), 4.33 (d, 1 H, J1,2 = 9.5 Hz, H-1),
4.12 (t, 1 H, J2,3 = J2,1 = 9.4 Hz, H-2), 3.89–3.81 (m, 2 H, H-4, H-6a),
3.75–3.64 (m, 2 H, H-5, H-6b), 3.55 (dd, 1 H, J3,4 = 3.3 Hz, H-3),
2.56 ppm (s, 3 H, Me); 13C NMR (75.4 MHz, CD3OD): d= 164.8
(COOBn), 162.0, 142.3 (C-2’, C-5’), 137.7 (Cq-Ar), 129.6, 129.3, 129.2
(C-Ar), 115.9 (C-4’), 114.2 (C-3’), 91.2 (C-1), 82.2 (C-5), 75.7 (C-3), 70.2
(C-4), 67.5 (C-2), 67.1 (CH2Ph), 62.8 (C-6), 50.9 (CH2S), 13.9 ppm
(Me); HRESIMS: m/z found 479.0976; calcd For C20H24O10NaS (M +
Na)+ : 479.0982.
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((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-sulfonyl-a-
d-galactopyranoside (7): To a solution of 17 (56 mg, 0.090 mmol)
in anhydrous MeOH (1.5 mL), NaOMe (18 mL, 0.5 m in MeOH) was
added and the mixture stirred at 0 8C for 2 h. Then, the mixture
was neutralized with Amberlite IR-120H+ , filtered, and washed
with MeOH. The filtered solution was concentrated to give pure 7
(32 mg, 0.070 mmol, 78 %) as a white solid. a½ A26D = 91.8 (c = 0.98,
MeOH); IR: = 3382 (OH), 2925, 1713 (C=O), 1080 cm@1; 1H NMR
(300 MHz, CD3OD): d= 7.43–7.29 (m, 5 H, H-Ar), 6.80 (s, 1 H, H-3’),
5.27 (s, 2 H, CH2Ph), 5.09 (d, 1 H, J1,2 = 6.0 Hz, H-1), 4.70 (d, 1 H,
2JH,H = 14.9 Hz, CH2S), 4.50 (d, 1 H, CH2S), 4.37–4.24 (m, 3 H, H-2, H-3,
H-4), 4.00–3.99 (m, 1 H, H-5), 3.82 (dd, 1 H, 2J6a,6b = 11.8, J6a,5 = 7.3 Hz,
H-6a), 3.71 (dd, 1 H, J6b,5 = 4.4 Hz, H-6b), 2.55 ppm (s, 3 H, Me);
13C NMR (75.4 MHz, CD3OD): d= 164.7 (COOBn), 161.9, 142.6 (C-2’,
C-5’), 137.6 (Cq-Ar), 129.6, 129.3, 129.2 (C-Ar), 115.8 (C-4’), 114.0 (C-
3’), 90.9 (C-1), 78.7, 70.7, 69.2 (C-2, C-3, C-4), 70.0 (C-5), 67.1
(CH2Ph), 62.6 (C-6), 52.8 (CH2S), 13.9 ppm (Me); HRESIMS: m/z
found: 479.0971; calcd For C20H24O10NaS (M + Na)
+ : 479.0982.
((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-sulfinyl-b-d-
galactopyranoside (8): To a @78 8C solution of 16 (142 mg,
0.24 mmol) in CH2Cl2 (5 mL), MCPBA (59 mg, 0.24 mmol) was
added and the mixture stirred at @78 8C!@30 8C for 3 h. Then, a
sat. aq. solution of NaHCO3 was added and the mixture was ex-
tracted with CH2Cl2. The combined organic phases were washed
with a sat. aq. solution of NaHCO3 and brine, dried over Na2SO4, fil-
tered, and evaporated. The resulting residue was purified by
column chromatography on silica gel (EtOAc/cyclohexane 1:1!1:1)
to give 20 (100 mg, 0.164 mmol, 68 %) as a white solid. To a solu-
tion of this compound (60 mg, 0.099 mmol) in anhydrous MeOH
(2 mL), NaOMe (20 mL, 0.5 m in MeOH) was added and the mixture
stirred at 0 8C for 1 h. Then, the mixture was neutralized with Am-
berlite IR-120H+ , filtered, and washed with MeOH. The filtered so-
lution was concentrated and the residue was purified by column
chromatography on silica gel (CH2Cl2/MeOH 10:1!8:1) to give 8
(28 mg, 0.064 mmol, 65 %) as a white solid. a½ A27D =@73.5 (c = 0.82,
MeOH); IR: = 3341 (OH), 2929, 1713 (C=O), 1072 cm@1; 1H NMR
(300 MHz, CD3OD, 1.5:1 mixture of diastereoisomers A/B): d= 7.43–
7.28 (m, H-Ar(A), H-Ar(B)), 6.76, (s, H-3’(B)), 6.75 (s, H-3’(A)), 5.31–
5.23 (m, CH2Ph(A), CH2Ph(B)), 4.42–4.33 (m, H-1(A), CH2S(A),
CH2S(B)), 4.03–3.55 (m, H-1(B), H-2(A), H-2(B), H-3(A), H-3(B), H-4(A),
H-4(B), H-5(A), H-5(B), H-6(A), H-6(B)), 2.56 ppm (s, Me(A)) 2.55 (s,
Me(B)) ; 13C NMR (75.4 MHz, CD3OD, mixture of diastereoisomers):
d= 164.8, 164.7 (COOBn(A), COOBn(B)), 161.83, 161.77, 144.7 (C-
2’(A), C-2’(B), C-5’(A), C-5’(B)), 137.7 (Cq-Ar), 129.6, 129.3, 129.2 (C-
Ar), 115.8 (C-4’), 113.4, 113.2 (C-3’(A), C-3’(B)), 93.8 (C-1(A)), 90.8 (C-
1(B)), 82.4, 82.3, 76.3, 76.1, 70.8, 70.3, 68.2, 66.5, (C-2(A), C-2(B), C-
3(A), C-3(B), C-4(A), C-4(B), C-5(A), C-5(B)), 67.1 (CH2Ph), 62.9, 62.8
(C-6(A), C-6(B)), 46.6, 46.1 (CH2S(A), CH2S(B)), 13.9 ppm (Me); HRE-
SIMS: m/z found: 463.1024; calcd for C20H24O9NaS (M + Na)
+ :
463.1033.
((4-Benzyloxycarbonyl-5-methylfuran-2-yl)methyl)-1-sulfinyl-a-d-
galactopyranoside (9): To a @78 8C solution of 15 (100 mg,
0.169 mmol) in CH2Cl2 (3.5 mL), MCPBA (42 mg, 0.17 mmol) was
added and the mixture stirred at @78 8C!@30 8C for 2 h. Then, a
sat. aq. solution of NaHCO3 was added and the mixture was ex-
tracted with CH2Cl2. The combined organic phases were washed
with a sat. aq. solution of NaHCO3, water, and brine, dried over
Na2SO4, filtered, and evaporated. The resulting residue was purified
by column chromatography on silica gel (Et2O/cyclohexane 4:1!
3:1) to give 19 (66 mg, 0.11 mmol, 65 %) as a white solid. To a solu-
tion of this compound (20 mg, 0.034 mmol) in anhydrous MeOH
(0.7 mL), NaOMe (7 mL, 0.5 m in MeOH) was added and the mixture
stirred at 0 8C for 1 h. Then, the mixture was neutralized with Am-
berlite IR-120H+ , filtered, and washed with MeOH. The filtered so-
lution was concentrated and the residue was purified by column
chromatography on silica gel (EtOAc/MeOH 5:1) to give 9 (11 mg,
0.025 mmol, 74 %) as a pale-yellow oil. a½ A27D = 195.5 (c = 0.67,
MeOH); IR: = 3369 (OH), 2923, 1710 (C=O), 1079 cm@1; 1H NMR
(300 MHz, CD3OD, single diastereoisomer): d= 7.43–7.29 (m, 5 H, H-
Ar), 6.78 (s, 1 H, H-3’), 5.27 (s, 2 H, CH2Ph), 4.75 (d, 1 H, J1,2 = 4.2 Hz,
H-1), 4.44 (d, 1 H, 2JH,H = 14.5 Hz, CH2SO), 4.28 (dd, 1 H, J2,3 = 7.7 Hz,
H-2), 4.24 (d, 1 H, CH2SO), 4.07–4.05 (m, 1 H, H-5), 4.00 (dd, 1 H,
J3,4 = 3.3 Hz, H-3), 3.96–3.88 (m, 2 H, H-4, H-6a), 3.76–3.68 (m, 1 H, H-
6b), 2.56 ppm (s, 3 H, Me); 13C NMR (75.4 MHz, CD3OD, single dia-
stereoisomer): d= 164.8 (COOBn), 161.8, 144.6 (C-2’, C-5’), 137.7
(Cq-Ar), 129.6, 129.22, 129.19 (C-Ar), 115.7 (C-4’), 113.5 (C-3’), 92.0
(C-1), 80.3 (C-4), 72.3 (C-3), 69.9 (C-2), 68.8 (C-5), 67.1 (CH2Ph), 61.5
(C-6), 47.8 (CH2SO), 13.9 ppm (Me); HRESIMS: m/z found: 463.1024;
calcd For C20H24O9NaS (M + Na)
+ : 463.1033.
Weak affinity chromatography
Recombinant CTB (SBL vaccines, Stockholm, Sweden) was immobi-
lized onto Nucleosil silica (10 mm, 300 a) and packed into a 50 V
2.1 mm column. The number of active groups of CTB was estimat-
ed to be 261 nmol. All chromatographic experiments were per-
formed with an Agilent-1100/Agilent-1200 HPLC system. The
mobile phase was 10 mm sodium phosphate, 0.15 mm sodium
chloride, pH 7. The flow rate was 0.1 mL min@1 and the temperature
22 8C. The sample volume was 5 mL and the sample concentration
35 mm. Detection was performed at 220 nm. The retention factor
(k’) and the affinity (KD) of the derivatives were calculated as de-
scribed previously,[21, 30] by using 3NPG as the reference compound
(KD = 1.06:0.04 mm).
Nuclear magnetic resonance spectroscopy
Ligands 4–9 were assigned by performing COSY, TOCSY, and HSQC
experiments on a 2 mm solution of the ligands dissolved in D2O,
[D6]DMSO 5 %. For the STD NMR build-up curves, sample contain-
ing 1 mm substrate (ligands 4–9) and 5 mm CTB (each pentamer
contains 5 equivalent binding sites), that is, protein/ligand ([P]/[L])
ratio of 1:40, were prepared. The build-up curves were acquired
with irradiation frequency 0.60 ppm, at 0.5, 1, 2, 3, 4, and 5 s, with
a delay between experiment of 5 s and 256 scans. For the DEEP-
STD NMR fingerprinting approach and on-resonance scanning of
3NPG and ligands 4–7, STD NMR experiments at 2 s saturation
time and 32 scans were performed at the irradiation frequencies of
0.60 ppm and 2.25 ppm.
The STD NMR competitions experiments were performed on sam-
ples constituted of 1 mm ligand and 5 mm CTB (each pentamer
contains 5 equivalent binding sites), that is, protein/ligand ([P]/[L])
ratio of 1:40. First, the STD NMR experiment of the ligand under in-
vestigation (ligand 2 or 3) was performed (saturation time 2 s,
delay between experiments 5 s and 512 scans; the competitor
ligand in equimolar concentration was freeze dried and added to
the sample, then the experiment was repeated. Exchange-trans-
ferred-NOESY (tr-NOESY) experiments were performed with [P]/
[L] = 1:10 on the ternary complex of ligand 3 and 3NPG with CTB
(1 mm of each ligand and 20 mm CTB), with mixing time 1.2 s,
delay 2 s, and 160 scans. As a control, the same experiment was
performed on 3NPG/CTB, ligand 3/CTB, and CTB alone in the same
conditions. All the NMR experiments were performed at 278 K.
An STD pulse sequence that included 2.5 ms and 5 ms trim pulses
and a 3 ms spoil gradient and water suppression by excitation
sculpting with gradients was used (stddiffesgp.3). Saturation was
achieved by applying a train of 50 ms Gaussian pulses (0.40 mW)
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on the f2 channel, at 0 ppm or 7.27 ppm (on-resonance experi-
ments) and 40 ppm (off-resonance experiments). The broad protein
signals were removed by using a 40 ms spinlock (T11) filter
(stddiff.3). Tr-NOESY experiments were performed by using a
phase-sensitive pulse program with gradient pulses in the mixing
time and a relaxation delay of 2 s, with water suppression using a
3–9–19 pulse sequence with gradients (noesyfpgpph19).[34, 35, 36] All
the experiments were recorded at 1H frequency of 800.23 MHz
with a Bruker Avance III spectrometer equipped with a 5-mmD
probe TXI 800 MHz H-C/N-D-05 Z BTO.
Protein–ligand docking calculations
All molecular modeling was performed with the module Glide
within Schrçdinger’s Maestro modeling suite.[24, 25, 26] Coordinates
for CTB were obtained from the Protein Data Bank (3CHB) for the
closed conformation and from a representative frame of our
HREMD trajectory of the GM1/CTB complex for the open conforma-
tion. Where necessary, coordinates for missing atoms were added
according to known protein chemistry and side chain protonation
was optimized for neutral pH. A short energy minimization was
run by using the OPLS3 force field, converging heavy atoms to a
RMSD of 0.3 a. The receptor grid was then calculated, centering on
the centroid of GM1 and with a length of 30 a to encompass all
subsites. Three-dimensional structures of all ligands were generat-
ed by using a conformational search, implementing Monte-Carlo
torsional sampling, keeping only unique structures (RMSD>0.5 a)
and eliminating all structures with an energy 21 kJ mol@1 greater
than the lowest energy structure. All resulting structures were then
energy minimized by using conjugate gradient minimization, con-
verging on a threshold of 0.05 kJ mol@1 a@1. For each ligand, the
ten lowest energy conformations were used to initiate docking.
The docking consisted of further conformer sampling (generation
of ring conformations switched off, to avoid potential generation
of distorted galactopyranose ring conformations out of the well-
known low energy range around the 4C1 conformation), docking,
and then energy minimization. Conformers were generated with
4 V enhanced sampling and, during docking, the non-bonded term
of the potential energy function was softened for nonpolar ligand
atoms (charge < j0.15 j) by applying a scaling factor of 0.8. Finally,
energy minimization was performed by using implicit solvent with
a distance dependent dielectric constant of 4.
Molecular dynamics: derivation of charges
The charges of all protein and carbohydrate atoms were obtained
from AMBER ff14SB and GLYCAM 06j libraries, respectively. The
charges of organics moieties were derived by using the RESP fit-
ting method implemented on the RED server,[37] following a similar
protocol to previous publications.[38, 39, 40] The non-carbohydrate re-
gions of both ligands 2 and 3 were each split into two fragments
to increase computational efficiency, by disconnecting the bond
between the sulfur and the anomeric carbon. In place of this bond,
both ends were capped with a methyl group. Charges of individual
fragments were computed by using the HF/6-31G* level of theory
with a weight factor of 0.01. All aliphatic protons were constrained
to a charge of 0. During the fitting, the combined charge of the
starred methyl and hydroxyl groups was set to zero, removing
these groups in the final fitting and merging the fragments to give
the full-length non-carbohydrate moiety. For ligand 2, the charge
of the sulfide methyl group was set to 0.194 throughout the fitting
stages before removing to give a final fragment with net charge
@0.194, in keeping with the modularity of the GLYCAM forcefield
used for galactose charges.
Molecular dynamics: initial coordinates
Initial coordinates for simulations of free CTB and the GM1/CTB
complex were obtained from the Protein Data Bank (3CHB). Unre-
solved atoms were added to the coordinate files by using tleap, ac-
cording to known protein chemistry and protonation state at phys-
iological pH. Coordinates for simulations involving ligands 2 and 3
were generated by molecular docking as described above.
Molecular dynamics: simulation protocol
All systems were parameterized by using AMBER ff14SB, GLYCAM_
06j, and GAFF forcefields for the protein, carbohydrate, and organ-
ic moieties, respectively. Model systems were generated by solvat-
ing with explicit TIP4PEW water molecules within a truncated octa-
hedral bounding box such that no solute atom was less than 10 a
from any face. An appropriate number of chloride ions were added
to each system to neutralize the total charge. Conjugate gradient
energy minimization was run with 100 kcal mol@1 a@2 restraints on
solute atoms, converging on a threshold of 1 V 10@4 kcal mol@1 a@1,
before repeating with no restraints. The system was then heated at
constant volume to 300 K over a period of 100 ps by using a weak
coupling algorithm with a time constant of 1 ps, employing peri-
odic boundary conditions (PBC) with the particle mesh Ewald
(PME) method. A constant temperature and pressure (1 atm) simu-
lation was then run for 200 ps, using PBC with PME, to equilibrate
the solvent density. A Langevin thermostat with a collision fre-
quency of 2 ps@1 and a Berendsen barostat with a relaxation time
of 2 ps were used. The SHAKE algorithm was used to restrain all
bonds involving hydrogen, allowing a timestep of 2 fs to be used.
A cutoff of 8 a was used for non-bonded interactions at all simula-
tion stages. Using the same settings as for equilibration, classical
molecular dynamics simulations were run for 100 ns, saving trajec-
tory coordinates every 5 ps. For HREMD simulations, systems were
prepared as above, differing only in the production dynamics
stage. Eight replicas were generated from the same initial coordi-
nates following equilibration and were each run for 12.5 ns. The
non-bonded potential between solvent atoms and non-polar pro-
tein atoms (defined as carbon and sulfur) were scaled by a factor
between 1 and 1.35 at intervals of 0.05 and exchanges between
replicas was allowed every 2 ps. All trajectories were analyzed with
cpptraj. All molecular graphics were generated with Schrodinger
Maestro 11 version 2016-4.
CORCEMA-ST predictions[28, 41]
Based on the experimental conditions, the concentration of ligand
was 1 mm and the [P]/[L] ratio was kept fixed at 25:1. The cut dis-
tance around the binding pocket was 13 a. kon was set to 1 V
10@8 m@1 and the irradiation frequency to the range @0.8 to
0.8 ppm. The bound ligand correlation time (t) was 65 ns for both
ligands, whereas the free correlation time was 1.2 ns, 1 ns, and
1 ns, respectively for ligands 2, 1, and 3. The equilibrium constant
used for ligand 2 was 2000 m@1, 1000 m@1 for ligand 1, and
1500 m@1 for ligand 3, with 1 leak of 0.25. For ligands 2 and 3, COR-
CEMA-ST calculations were run in parallel on the High-Performance
Computing Unit, and then averaged to provide a representative
build-up curve for each ligand. The NOE R-factor was calculated on
the averaged simulated data obtained accordingly.
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